Show simple item record

dc.contributor.authorMasri, Selma
dc.contributor.authorKinouchi, Kenichiro
dc.contributor.authorSassone-Corsi, Paolo
dc.date.accessioned2016-02-25T12:56:32Z
dc.date.available2016-02-25T12:56:32Z
dc.date.issued2015-01
dc.identifier.citationMasri S, Kinouchi K, Sassone-Corsi P (2015) Circadian clocks, epigenetics, and cancer. Current Opinion in Oncology 27: 50–56. Available: http://dx.doi.org/10.1097/CCO.0000000000000153.
dc.identifier.issn1040-8746
dc.identifier.pmid25405464
dc.identifier.doi10.1097/CCO.0000000000000153
dc.identifier.urihttp://hdl.handle.net/10754/597777
dc.description.abstractThe interplay between circadian rhythm and cancer has been suggested for more than a decade based on the observations that shift work and cancer incidence are linked. Accumulating evidence implicates the circadian clock in cancer survival and proliferation pathways. At the molecular level, multiple control mechanisms have been proposed to link circadian transcription and cell-cycle control to tumorigenesis.The circadian gating of the cell cycle and subsequent control of cell proliferation is an area of active investigation. Moreover, the circadian clock is a transcriptional system that is intricately regulated at the epigenetic level. Interestingly, the epigenetic landscape at the level of histone modifications, DNA methylation, and small regulatory RNAs are differentially controlled in cancer cells. This concept raises the possibility that epigenetic control is a common thread linking the clock with cancer, though little scientific evidence is known to date.This review focuses on the link between circadian clock and cancer, and speculates on the possible connections at the epigenetic level that could further link the circadian clock to tumor initiation or progression.
dc.description.sponsorshipWork in the Sassone-Corsi laboratory is supported by the National Institute of Health (NIH), INSERM (Institut National de la Sante et la Recherche Medicale, France), KAUST (King Abdullah University of Science and Technology, Saudi Arabia), and Merieux Pharmaceuticals (France). S.M. is supported by the UC Irvine Chao Family Cancer Center and K.K. is supported by a JSPS postdoctoral fellowship.
dc.publisherOvid Technologies (Wolters Kluwer Health)
dc.subjectCancer
dc.subjectCell cycle
dc.subjectCircadian clock
dc.subjectEpigenome
dc.subjectMetabolism
dc.subject.meshNeoplasms
dc.subject.meshEpigenesis, Genetic
dc.titleCircadian clocks, epigenetics, and cancer
dc.typeArticle
dc.identifier.journalCurrent Opinion in Oncology
dc.identifier.pmcidPMC4732884
dc.contributor.institutionDepartment of Biological Chemistry, Center for Epigenetics and Metabolism, University of California, Irvine, Irvine, California, USA.


This item appears in the following Collection(s)

Show simple item record